[go: up one dir, main page]

MX2011007381A - Composicion farmaceutica que contiene aleglitazar. - Google Patents

Composicion farmaceutica que contiene aleglitazar.

Info

Publication number
MX2011007381A
MX2011007381A MX2011007381A MX2011007381A MX2011007381A MX 2011007381 A MX2011007381 A MX 2011007381A MX 2011007381 A MX2011007381 A MX 2011007381A MX 2011007381 A MX2011007381 A MX 2011007381A MX 2011007381 A MX2011007381 A MX 2011007381A
Authority
MX
Mexico
Prior art keywords
aleglitazar
pharmaceutical composition
relates
manufacture
control
Prior art date
Application number
MX2011007381A
Other languages
English (en)
Inventor
Alexander Glomme
Paul Wojtera
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2011007381A publication Critical patent/MX2011007381A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La invención se refiere a una composición farmacéutica que contiene el aleglitazar, al proceso de fabricación y a los usos de la misma.
MX2011007381A 2009-01-23 2010-01-13 Composicion farmaceutica que contiene aleglitazar. MX2011007381A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09151254 2009-01-23
PCT/EP2010/050343 WO2010084066A1 (en) 2009-01-23 2010-01-13 Pharmaceutical composition comprising aleglitazar

Publications (1)

Publication Number Publication Date
MX2011007381A true MX2011007381A (es) 2011-08-12

Family

ID=42112184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007381A MX2011007381A (es) 2009-01-23 2010-01-13 Composicion farmaceutica que contiene aleglitazar.

Country Status (25)

Country Link
US (2) US20100190835A1 (es)
EP (1) EP2389166B1 (es)
JP (1) JP5619027B2 (es)
KR (2) KR20110105798A (es)
CN (1) CN102292074B (es)
AR (1) AR075041A1 (es)
AU (1) AU2010206249B2 (es)
BR (1) BRPI1007237B1 (es)
CA (1) CA2748896C (es)
CL (1) CL2011001777A1 (es)
CY (1) CY1113641T1 (es)
DK (1) DK2389166T3 (es)
ES (1) ES2397558T3 (es)
HR (1) HRP20130108T1 (es)
IL (1) IL213671A (es)
MX (1) MX2011007381A (es)
PE (2) PE20160746A1 (es)
PL (1) PL2389166T3 (es)
PT (1) PT2389166E (es)
RU (1) RU2537224C2 (es)
SG (1) SG173058A1 (es)
SI (1) SI2389166T1 (es)
TW (1) TWI406861B (es)
WO (1) WO2010084066A1 (es)
ZA (1) ZA201104670B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181384A1 (en) 2012-05-31 2013-12-05 Ratiopharm Gmbh Solid state forms of aleglitazar sodium
WO2014016370A1 (en) * 2012-07-27 2014-01-30 Ratiopharm Gmbh Amorphous aleglitazar
WO2014016371A1 (en) 2012-07-27 2014-01-30 Ratiopharm Gmbh Micronized aleglitazar
WO2014016369A1 (en) 2012-07-27 2014-01-30 Ratiopharm Gmbh Pharmaceutical formulation comprising aleglitazar and complexing agent
WO2014040936A1 (en) * 2012-09-12 2014-03-20 F. Hoffmann-La Roche Ag Solid forms of (s)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid and of salts thereof
CN116172869A (zh) * 2016-08-10 2023-05-30 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
CN114404375B (zh) * 2022-01-21 2023-06-27 武汉九珑人福药业有限责任公司 一种叶酸固体制剂及其原料组合物、制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
NZ529033A (en) * 2001-05-15 2005-06-24 F Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes
GB0303600D0 (en) * 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
BRPI0606187A2 (pt) * 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
US20060270722A1 (en) * 2005-05-31 2006-11-30 Thornberry Nancy A Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity
FR2894477A1 (fr) * 2005-12-13 2007-06-15 Galderma Res & Dev Utilisation du naveglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques
US20100210692A1 (en) * 2007-03-28 2010-08-19 Farmer Stephen R Methods of treatment using sirt modulators and compositions containing sirt1 modulators

Also Published As

Publication number Publication date
AU2010206249A1 (en) 2011-06-30
US20100190835A1 (en) 2010-07-29
TWI406861B (zh) 2013-09-01
CN102292074A (zh) 2011-12-21
CY1113641T1 (el) 2016-06-22
JP5619027B2 (ja) 2014-11-05
CA2748896C (en) 2017-01-03
PT2389166E (pt) 2013-01-08
CN102292074B (zh) 2013-08-21
HRP20130108T1 (hr) 2013-03-31
CL2011001777A1 (es) 2012-02-24
BRPI1007237B1 (pt) 2019-05-28
IL213671A (en) 2015-11-30
EP2389166B1 (en) 2012-11-21
ZA201104670B (en) 2012-03-28
PE20120421A1 (es) 2012-05-04
PE20160746A1 (es) 2016-08-01
IL213671A0 (en) 2011-07-31
PL2389166T3 (pl) 2013-04-30
SI2389166T1 (sl) 2013-02-28
RU2537224C2 (ru) 2014-12-27
AR075041A1 (es) 2011-03-02
JP2012515741A (ja) 2012-07-12
AU2010206249B2 (en) 2015-07-09
KR20140002812A (ko) 2014-01-08
WO2010084066A1 (en) 2010-07-29
EP2389166A1 (en) 2011-11-30
SG173058A1 (en) 2011-08-29
US20130072529A1 (en) 2013-03-21
CA2748896A1 (en) 2010-07-29
KR20110105798A (ko) 2011-09-27
ES2397558T3 (es) 2013-03-07
DK2389166T3 (da) 2012-12-17
TW201035089A (en) 2010-10-01
BRPI1007237A2 (pt) 2016-02-16
RU2011134964A (ru) 2013-02-27

Similar Documents

Publication Publication Date Title
MX2011007381A (es) Composicion farmaceutica que contiene aleglitazar.
WO2008003572A3 (de) Bedieneinheit zur anzeige und/oder einstellung von betriebsparameterwerten von zumindest einem hausgerät
EP3608403A3 (en) Detergent composition comprising subtilase variants
MX336737B (es) Composiciones y metodos que comprenden variantes de proteasa serina.
WO2010056640A3 (en) Compositions and methods comprising serine protease variants
MY189197A (en) Herbicidal composition comprising cinmethylin and acetochlor or pretilachlor
MX2009004329A (es) Estructuras fibrosas de tela no tejida parecidas a la tela y procesos para fabricarlas.
EP3486319A3 (en) Compositions and methods comprising serine protease variants
WO2011072099A3 (en) Compositions and methods comprising protease variants
WO2011130222A3 (en) Compositions and methods comprising variant proteases
WO2017087901A3 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
EP4339282A3 (en) Liquid cleaning compositions comprising protease variants
BRPI0704398A2 (pt) estabilizadores de alofanato modificado e os polìmeros de polióis preparados destes estabilizadores
BR112016005286A2 (pt) composições e métodos compreendendo variantes de protease do clado lg12
TW200626171A (en) Fixed dosing of HER antibodies
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
ATE535640T1 (de) Haushaltsstandgerät
MX2007012867A (es) Producto instantaneo.
PH12014501169B1 (en) Thrombin-binding antibody molecules and uses thereof
WO2010084064A3 (de) Bedienvorrichtung eines haushaltsgeräts
MX2011012248A (es) Anticuerpos o sus fragmentos dirigidos contra un epitope de staphylococcus aureus de isaa o isab.
ATE499439T1 (de) Subtilasen
MX2009009831A (es) Nitrilos aromatizantes.
ATE444990T1 (de) Spritzbare akustikmassen
WO2011023540A3 (de) Verwendung von cycloaliphatischen diolen als biozide

Legal Events

Date Code Title Description
FG Grant or registration